ChinaBio® Executive Workshop
The Age of Personalized Medicine: Trends and Opportunities Reflected in the U.S. Experience
Hosted by: Foley & Lardner LLP
Date: April 17, 2013 (Wednesday)
Location: Grand Hyatt Shanghai
Time: 08:30 --- 12:00
Under the banner of "personalized medicine," global health care is on the cusp of profound revolutionary changes. A confluence of 21st century innovations — from genomics and proteomics to Big Data analysis and dissemination — makes very real the potential to tailor medical treatments to the specific characteristics of each patient.
Foley and ChinaBio invite you to join us for our upcoming executive workshop, which will explore this paradigm shift toward personalized medicine and its global implications for China's life sciences business executives, health care professionals, and academic researchers.
Topics to be discussed include:
- Business and social factors driving the move to personalized medicine, including non-sustainable medical costs, a decline in pharma R&D productivity, and the rise of patient-oriented health care
- Regulatory and intellectual property challenges to formulating a viable business model in the personalized medicine arena
- Potential for strategic collaborations with U.S. companies focused on different aspects of personalized medicine, such as genomic sequencing, biomarker substantiation, genetic testing, and electronic health records
- Post-grant patent issues, reducing patent litigation cost, and other risk management issues in the United States
|8:30 - 9:00
||Registration and Breakfast
|9:05 - 9:30
||Trends of China's life Sciences Industry
- Greg B. Scott, President and Founder, ChinaBio® LLC
|9:30 - 10:00
||Personalized Medicine: Promise and Challenges for U.S. and China
- Alex Y. Nie, Associate, Foley & Lardner LLP
|10:00 - 10:30
||What Personalized Medicine Companies Should Know About China IP Laws
- Max Song Lin, China Associate, Foley & Lardner LLP
|10:30 - 10:45
||Q & A
|10:45 - 11:00
|11:00 - 11:30
The Regulatory Climate for Personalized Medicine: U.S. and China
|11:30 - 12:00
||Mitigating Patent Infringement Risks for PM in the U.S.
- Andrew S. Baluch, Special Counsel, Foley & Lardner LLP
|12:00 - 12:15
||Q & A|
Andrew Baluch, JD - Intellectual Property Special Counsel, Foley & Lardner LLP
Andrew Baluch is an Intellectual Property law special counsel with Foley & Lardner LLP. He advises companies on global IP strategies, including international portfolio management, IP diligence reviews, opinions, licensing, litigation, patent reexamination, and trade secret protection. As a member of the firm's China practice, Mr. Baluch provides clients with information on the impact of the Chinese legal environment and consultancy on U.S. law and international conventions, including the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) and the Anti-Counterfeiting Trade Agreement (ACTA). Mr. Baluch is a former director of international IP enforcement in the White House Office of the IP Enforcement Coordinator. Prior to his White House appointment, he was an expert legal advisor to the under secretary and director of the U.S. Patent & Trademark Office (USPTO).
Nathan A. Beaver, JD – Partner, Foley & Lardner LLP
Nathan A. Beaver is a partner with Foley & Lardner LLP. His practice focuses on the representation of manufacturers whose products and activities are regulated by the Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), and the Federal Trade Commission (FTC). He advises clients on regulatory issues affecting prescription and over-the-counter drug products (including animal drugs), medical devices, dietary supplements, cosmetics, and foods with special emphasis on the strategic considerations involving the approval process and patent and exclusivity issues related to the Hatch-Waxman Act. Mr. Beaver is a member of the firm’s Government & Public Policy and FDA Practices, and the Food & Beverage Industry and Life Sciences Industry Teams. Mr. Beaver also has significant experience in FDA and Hatch-Waxman cases involving drug approvals, withdrawals and other types of litigation involving FDA regulated products.
Song (Max) Lin, LLM – China Associate, Foley & Lardner LLP
Song (Max) Lin is a China associate with Foley & Lardner LLP, where his practice focus is on intellectual property (IP) law relating to China. Mr. Lin has experience with a broad spectrum of patent and trademark issues. He is also a member of the Nanotechnology Industry Team. Prior to joining Foley, Mr. Lin was an intern at a leading Chinese law firm dedicated exclusively to intellectual property matters. During his internship, Mr. Lin worked on litigation, licensing, opinion and patent prosecution matters in the areas of patent and trademark law. While in law school, Mr. Lin published several articles involving patent and trademark law.
Alex Y, Nie, JD, PhD – Associate, Foley & Lardner LLP
Alex Y. Nie, an associate with Foley & Lardner LLP, is a member of the firm’s Chemical, Biotechnology & Pharmaceutical and Electronics Practices and the Life Sciences Industry Team. Dr. Nie’s practice entails the procurement of patents and related counseling in matters in life science and information technology. With respect to life science, Dr. Nie’s focus is on personalized medicine, computational biology and chemistry, in vitro diagnostics and stem cell technology in addition to conventional biotechnology and pharmaceuticals. Within information technology, Dr. Nie’s practice relates to general software and hardware, such as those involving machine learning methods, encryption technologies, mobile platform and digital circuit design.
Greg B. Scott - President and Founder, ChinaBio® LLC
Greg founded ChinaBio® LLC in January 2007 to bring together Chinese and Western life science companies to better leverage China's rapidly growing life science markets. ChinaBio works with U.S. and European companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio has also organized over 30 conferences in China focused on investment and partnering, and is holding its fifth ChinaBio Partnering Forum in Beijing on May 29-30, 2013. This international event draws over 800 attendees from around the world, making it the largest partnering conference in China. Greg is also co-founder of two angel investment groups that have funded over 45 biotechnology and medical device companies in the U.S. and China since 2005, and Executive Editor of ChinaBio® Today, the most widely read source for China life science news. Greg lives and works in Shanghai but visits the U.S. several times a year to enjoy California's blue sky and sandy beaches.
This ChinaBio® Executive Workshop – Shanghai will be held at:
Grand Hyatt Shanghai (??????) ?????
Conference Room I, 1F
Address: Jin Mao Tower, 88 Century Avenue, Pudong, Shanghai
200121, China Local Map
Tel: +86 21 5049 1234
- From Shanghai Pudong International Airport, 45 min, 180 RMB (one way)
- From Shanghai Hongqiao International Airport, about 45 min, 110 RMB (one way)
- From the Shanghai Railway Station, about 30min, 50 RMB (one way)
For driving directions, please contact the hotel.
We would like to thank Foley & Lardner for hosting this seminar:
- Foley & Lardner LLP – Foley is a highly regarded, international law firm providing client-focused, industry-specific services that result in high-value legal counsel for our clients. Our practice areas encompass the full range of corporate legal services. With an office located in Shanghai, the attorneys of Foley’s China Practice are well positioned to assist U.S., Asian, and European clients with the complex matters that arise when doing business in or related to Greater China. From IP procurement and technology transfer to M&A due diligence, count on Foley’s experience and our cultural and business connections in China to help you stake you claim. www.foley.com
We would also like to thank the following partners for making this event possible:
- BayHelix – BayHelix is an organization of leaders of Chinese origin in the global life sciences and healthcare community. We aspire to shape the growth of the life sciences and healthcare industry around the Pacific Rim and beyond, foster and create business opportunities, supply and nurture the leaders for the community, and network and share information and experience. BayHelix is a non-profit organization and its membership is by-invitation-only. www.bayhelix.org
- Bioon – Bioon are the leading life science portal in China. And professional registered members have more than 500 thousand; special 70% members are the master's -and doctoral qualifications. Our enterprises’ customers are more than 11 thousand, such as Invitrogen, Promega, Qiagen, Sigma, Pall. As the leading service- provider in China, we are committed to enhance the competition of our customers in life sciences. The following pipelines are our mature businesses: (1) www.bioon.com commitment to the field of life sciences media and brand promotion; (2) www.bioon.com.cn focused on our customers’ products -promotion, display and rankings, such as equipments, consumables, reagents and antibodies; Addition, we collected and sorted the serial of databases -including China lab database, professor database and region -based registered members database. These databases are the strong support and tool for customers marketing activity and marketing survey & analysis. Now, Bioon.com has become the preferred options to life sciences’ customers for professional seminar & training, targeting product promotion, brand -improvement and marketing survey & analysis. of professional customers in China. www.bioon.com
- ChinaBio® Today – China has surpassed Japan the second largest pharmaceutical market in the world, and is growing at an astounding 22% per year. Now, after billions of dollars of government and private investment, China is transforming itself into a world leader in biotechnology. ChinaBio® Today is the most widely read source focusing exclusively on China’s rapidly evolving life science industry, with over 18,000 readers. From our offices in Shanghai and San Diego, we provide daily news, commentary and analysis on public and private China life science companies, as well as global issues affecting the China market. www.ChinaBioToday.com.
About ChinaBio® LLC
Since its founding in January, 2007, ChinaBio® LLC has rapidly launched a number of initiatives accelerating the globalization of China’s life science industry. ChinaBio has helped China companies raise nearly $400 million and global life science companies identify over 400 licensing and acquisition opportunities in China.
- Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 4,000 attendees.
- Consulting: ChinaBio works with global life science companies and China entrepreneurs to define and execute a successful global strategy.
- Transactions: ChinaBio Capital helps companies secure partnerships and acquisitions and access private and government funding in China.
- Publishing: ChinaBio® Today is the most widely read online and email newsletter on China’s life science industry.
More information is available at www.ChinaBioLLC.com.